MEDIA RELEASE
For immediate release
23 October 2018
Waikato medicinal cannabis research company intends to list on NZX
In a first for New Zealand, medicinal cannabis research company Cannasouth has announced it will make an application to
list its shares on the NZX Main Board through an initial public offering (IPO) during the second calendar quarter of
2019.
Based in Waikato, Cannasouth has received a licence from the Ministry of Health to carry out medicinal cannabis research
in New Zealand. The licence also enables the company to apply for an import licence to import cannabis products for
research.
The granting of the license represents a major milestone for Cannasouth, whose management team has been involved in the
cultivation and research of industrial hemp, and now medicinal cannabis, since 2002.
Cannasouth’s director of operations Mark Lucas says the company’s IPO will open more doors for future research into the
development of advanced cannabinoid medicines and health-related products.
“The medicinal cannabis research industry is still very much in its early stages – we’ve only scratched the surface of
what is possible,” he says.
Cannasouth is currently planning the construction of GMP (good manufacturing processes) cultivation and production
facilities in Waikato, in anticipation of legislation changes that will allow the manufacture and sale of medicinal
cannabis in New Zealand.
The announcement of Cannasouth’s IPO comes after securing first round capital investment from the CMP Growth Capital
Fund, a fund that provides growth capital to emerging New Zealand businesses. It is anticipated that a further, modest
pre-IPO round of capital raising will be undertaken before the end of this year.
Sean Joyce, principal of CM Partners, which manages the CMP Growth Capital Fund, says Cannasouth has all of the
intellectual capital and attributes needed to be a leader in the medicinal cannabis industry.
“There is huge potential in this exciting emerging sector, and Cannasouth will be a welcome addition to the New Zealand
capital markets when it lists next year.”
Cannasouth is chaired by Australia-based director Tony Ho, who has significant listed company experience, and will be
joined on the board by former Federated Farmers CEO and experienced director Conor English. The board is further
supported by a scientific and medical advisory board which includes Emeritus Professor Alistair Wilkins from the
University of Waikato.
“We are delighted to have the support and backing of the CMP Growth Capital Fund and a wealth of experience and
expertise from Tony Ho, Conor English and the members of our advisory board,” says Lucas.
“Together we are excited about the future of the medicinal cannabis industry in New Zealand and the potential it has for
enhancing patient outcomes.”
Industry experience and expertise
Lucas, alongside Cannasouth’s director of research, Nicholas Foreman, received funding in 2016 from AGMARDT (the
Agricultural and Marketing Research and Development Trust) and Callaghan Innovation to undertake research projects with
the University of Waikato.
Cannasouth’s focus is on furthering medicinal cannabinoid research, specifically the extraction and refining of
cannabidiols (CBD).
CBD is a non-psychoactive compound in cannabis and has been associated with managing a range of medical conditions,
including cancer-related symptoms and neurological disorders such as epilepsy and multiple sclerosis.
Lucas says CBD, alongside THC (tetrahydrocannabidiol), are two of the more well-known compounds in medicinal cannabis
that have been shown to relieve patients’ suffering from a wide range of conditions, but there is significant potential
to learn more about the properties of other rarer compounds and how they can assist in treating medical conditions.
“We know current medicinal cannabis medicines are helping a lot of people, and it is our intention through ongoing,
rigorous research to start unlocking more treatment options to further improve patient outcomes.”
Plans for the future
Lucas says there has been significant interest from the public to invest in the medicinal cannabis sector, particularly
with the global industry moving ahead rapidly.
“The global medicinal cannabis market is exploding. Some estimates show it will reach $US28 billion within five years,
with other estimates placing it closer to $US50 billion,” he says.
“In New Zealand, we have a real opportunity to play a significant role in this market and position ourselves with our
focus on quality, innovation and sustainability.”
With its focus firmly on research and infrastructure development, Cannasouth is currently constructing a dedicated
facility in Waikato to cultivate a range of medicinal cannabis varieties for further research in its laboratory.
“Our goal is to become a world leader in the development of advanced, high-quality cannabinoid medicines to move beyond
what is currently available,” says Lucas.
“To do that, we’re focusing on our successful research model to enable further research and development that will
benefit the end user – the patient.”
ends